From excellence in cancer research to value for society
The ambition of the Center for Cancer Biology (CCB) is to contribute to a better understanding of the biology underlying cancer initiation, progression and metastatic dissemination. We aim to identify novel biomarkers for the early detection, monitoring of cancer progression and therapy response and, ultimately, develop more effective anticancer therapies.
Home
Our cancer center strives for excellence in basic cancer research and education, and explicitly seeks to translate its research findings into products and solutions that are of benefit for society. It is our ambition to explore every innovation and valorization opportunity into technology transfer activities or collaborations/partnerships with the pharmaceutical or biotech industry. We also pro-actively promote translational research and have the ultimate ambition to improve quality of life and patient survival by taking advantage of the close proximity and collaborative environment within the Leuven University (KU Leuven), its academic hospital (UZ Leuven) and other institutions worldwide.
CCB has a privileged geographic location on the KU Leuven Gasthuisberg campus (Leuven, Belgium). It is hosted by the KU Leuven university (the largest university in Flanders/Belgium) and physically connected to its internationally-recognized University Hospital UZ Leuven. In order to bridge basic and translational cancer research, the Leuven comprehensive cancer center (LKI) was created several years ago. LKI brings together fundamental researchers, oncologists, radiologists, pathologists, nurses, etc. that are involved in cancer care and/or cancer research. Being part of this large cancer hub and unique multidisciplinary landscape, CCB is ideally-located to be active on the whole cancer research continuum ranging from top-notch basic and preclinical cancer research to translational and early/late clinical research. However, excellence in basic cancer research is our main strength and key priority.